A MDP Model for Breast and Ovarian Cancer Intervention Strategies for BRCA1/2 Mutation Carriers

被引:15
|
作者
Abdollahian, Mehrnaz [1 ]
Das, Tapas K. [1 ]
机构
[1] Univ S Florida, Dept Ind & Management Syst Engn, Tampa, FL 33620 USA
关键词
BRCA1/2; mutations; hereditary breast and ovarian cancer; intervention strategies; Markov decision process (MDP); COST-EFFECTIVENESS; PREVENTION STRATEGIES; DECISION-ANALYSIS; WOMEN; SURVIVAL; SURGERY; RISK; TOOL;
D O I
10.1109/JBHI.2014.2319246
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Purpose: Women with BRCA1/2 mutations have higher risk for breast and ovarian cancers. Available intervention actions include prophylactic surgeries and breast screening, which vary significantly in cost, cancer prevention, and in resulting death from other causes. We present a model designed to yield optimal intervention strategies for mutation carriers between the ages of 30 and 65 and any prior intervention history. Methods: A Markov decision process (MDP) model is developed that considers yearly state transitions for the mutation carriers and state dependent intervention actions. State is defined as a vector comprising mutation type, health states, prior intervention actions, and age. A discounted value iteration algorithm is used to obtain optimal strategies from the MDP model using both cost and quality-adjusted life years (QALYs) as rewards. Results: The results from MDP model show that for 30-year-old women with BRCA1 mutation and no prior intervention history, the cost-optimal strategy is a combination of prophylactic mastectomy (PM) and prophylactic oophorectomy (PO) at age 30 with no screening afterwards. Whereas, the QALYs-optimal strategy suggests PO at age 30 and PM at age 50 with screening afterwards. For BRCA2 mutation carriers at age 30, the cost-optimal strategy is PO at age 30, PM at age 40, and yearly screening only after age 56. Corresponding QALYs-optimal strategy is PM at age 40 with screening. Strategies for all other ages (31 to 65) are obtained and presented. It is also demonstrated that the cost-optimal strategies offer near maximum survival rate and near minimum cancer incidence rates by age 70, when compared to other ad hoc strategies.
引用
收藏
页码:720 / 727
页数:8
相关论文
共 50 条
  • [31] Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers
    van den Broek, Alexandra J.
    van 't Veer, Laura J.
    Hooning, Maartje J.
    Cornelissen, Sten
    Broeks, Annegien
    Rutgers, Emiel J.
    Smit, Vincent T. H. B. M.
    Cornelisse, Cees J.
    van Beek, Mike
    Janssen-Heijnen, Maryska L.
    Seynaeve, Caroline
    Westenend, Pieter J.
    Jobsen, Jan J.
    Siesling, Sabine
    Tollenaar, Rob A. E. M.
    van Leeuwen, Flora E.
    Schmidt, Marjanka K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) : 409 - +
  • [32] Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
    Mavaddat, Nasim
    Barrowdale, Daniel
    Andrulis, Irene L.
    Domchek, Susan M.
    Eccles, Diana
    Nevanlinna, Heli
    Ramus, Susan J.
    Spurdle, Amanda
    Robson, Mark
    Sherman, Mark
    Mulligan, Anna Marie
    Couch, Fergus J.
    Engel, Christoph
    McGuffog, Lesley
    Healey, Sue
    Sinilnikova, Olga M.
    Southey, Melissa C.
    Terry, Mary Beth
    Goldgar, David
    O'Malley, Frances
    John, Esther M.
    Janavicius, Ramunas
    Tihomirova, Laima
    Hansen, Thomas V. O.
    Nielsen, Finn C.
    Osorio, Ana
    Stavropoulou, Alexandra
    Benitez, Javier
    Manoukian, Siranoush
    Peissel, Bernard
    Barile, Monica
    Volorio, Sara
    Pasini, Barbara
    Dolcetti, Riccardo
    Putignano, Anna Laura
    Ottini, Laura
    Radice, Paolo
    Hamann, Ute
    Rashid, Muhammad U.
    Hogervorst, Frans B.
    Kriege, Mieke
    van der Luijt, Rob B.
    Peock, Susan
    Frost, Debra
    Evans, D. Gareth
    Brewer, Carole
    Walker, Lisa
    Rogers, Mark T.
    Side, Lucy E.
    Houghton, Catherine
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (01) : 134 - 147
  • [33] Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma
    Mai, Phuong L.
    Chatterjee, Nilanjan
    Hartge, Patricia
    Tucker, Margaret
    Brody, Lawrence
    Struewing, Jeffery P.
    Wacholder, Sholom
    PLOS ONE, 2009, 4 (03):
  • [34] Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers
    Basu, Narendra Nath
    Evans, D. Gareth
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1066 - S1069
  • [35] Survival and recurrence after breast cancer in BRCA1/2 mutation carriers
    El-Tamer, M
    Russo, D
    Troxel, A
    Bernardino, LP
    Mazziotta, R
    Estabrook, A
    Ditkoff, BA
    Schnabel, F
    Mansukhani, M
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : 157 - 164
  • [36] Body weight and risk of breast cancer in BRCA1/2 mutation carriers
    Manders, Peggy
    Pijpe, Anouk
    Hooning, Maartje J.
    Kluijt, Irma
    Vasen, Hans F. A.
    Hoogerbrugge, Nicoline
    van Asperen, Christi J.
    Meijers-Heijboer, Hanne
    Ausems, Margreet G. E. M.
    van Os, Theo A.
    Gomez-Garcia, Encarna B.
    Brohet, Richard M.
    van Leeuwen, Flora E.
    Rookus, Matti A.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 193 - 202
  • [37] Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers
    Pijpe, Anouk
    Manders, Peggy
    Brohet, Richard M.
    Collee, J. Margriet
    Verhoef, Senno
    Vasen, Hans F. A.
    Hoogerbrugge, Nicoline
    van Asperen, Christi J.
    Dommering, Charlotte
    Ausems, Margreet G. E. M.
    Aalfs, Cora M.
    Gomez-Garcia, Encarna B.
    van't Veer, Laura J.
    van Leeuwen, Flora E.
    Rookus, Matti A.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (01) : 235 - 244
  • [38] Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers
    Mahmoud El-Tamer
    Donna Russo
    Andrea Troxel
    Lourdes P. Bernardino
    Robert Mazziotta
    Alison Estabrook
    Beth-Ann Ditkoff
    Freya Schnabel
    Mahesh Mansukhani
    Annals of Surgical Oncology, 2004, 11 : 157 - 164
  • [39] Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers
    Krammer, Julia
    Pinker-Domenig, Katja
    Robson, Mark E.
    Gonen, Mithat
    Bernard-Davila, Blanca
    Morris, Elizabeth A.
    Mangino, Debra A.
    Jochelson, Maxine S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 565 - 571
  • [40] Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Kotsopoulos, Joanne
    Huzarski, Tomasz
    Gronwald, Jacek
    Singer, Christian F.
    Moller, Pal
    Lynch, Henry T.
    Armel, Susan
    Karlan, Beth
    Foulkes, William D.
    Neuhausen, Susan L.
    Senter, Leigha
    Tung, Nadine
    Weitzel, Jeffrey N.
    Eisen, Andrea
    Metcalfe, Kelly
    Eng, Charis
    Pal, Tuya
    Evans, Gareth
    Sun, Ping
    Lubinski, Jan
    Narod, Steven A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (01):